Rethinking treatment for nervous system disorders
Empowering patients to live on their own terms

Who We Are

At its core, Eliem is motivated by the promise of helping people live happier, more fulfilling lives. The Eliem team channels its experience, energy and passion for improving patients’ quality of life by developing life-changing novel therapies for neuronal excitability disorders based on clinically validated mechanisms of action.

Our Approach: Optimizing Treatments for Neuronal Excitability Disorders

Tens of millions of people suffer from central and peripheral nervous system disorders, where an imbalance between excitation and inhibition has disrupted the homeostasis in affected neuronal networks. These disorders include a range of common conditions such as chronic pain, depression, epilepsy and anxiety. Currently available treatments for these conditions often fail to provide adequate control or relief, and they are often poorly tolerated, leaving people unable to live life on their own terms.

Developing improved treatments for patients requires a pragmatic and diligent approach. Equal parts rigorous and agile, the experienced Eliem team strives to make treatments that are more effective, safer and better tolerated than currently available treatments. Leveraging clinically validated mechanisms of action, we are moving steadily and efficiently to develop novel therapeutics for neuronal excitability disorders that deliver enhanced outcomes for patients.

Our Pipeline

Our clinical and preclinical pipeline is focused on neuronal excitability conditions of the central and peripheral nervous system. We are developing ETX-155 for major depressive disorder and focal onset seizures. This compound is designed to dramatically improve on the limitations of existing therapies with the potential to be best-in-class for these conditions with high unmet clinical needs.

Our Experienced Team

Eliem is founded and led by a team of seasoned industry executives who collectively bring decades of clinical development and biopharmaceutical commercialization experience to the company. The team not only shares an unparalleled determination and passion to help patients, but they also have a history of working together to successfully build companies and bring novel and effective therapies to market. Eliem is also advised by a Board with considerable neurology research and development experience and a strong track record of building successful companies.

The team’s combined expertise in neurological research, clinical development, commercialization and company building are critical for delivering on the promise of bringing innovative therapies to market to provide relief and hope for the millions of patients affected by neurological conditions.
Leadership Team
Board of Directors
Valerie Morisset, Ph.D.
Executive Vice President, R&D and Chief Scientific Officer
Jo Palmer-Phillips, Ph.D.
Chief Development Officer
Andrew Levin, M.D., Ph.D.
Judith Dunn, Ph.D.
Liam Ratcliffe, M.D., Ph.D.
Adam Rosenberg
Simon Tate


Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further
Load More


We are always looking to grow our team and believe it takes teamwork, trust and tenacity to deliver on the promise of helping patients live happier, more fulfilling lives. If this sounds like you, please indicate which position you are interested in and contact us at Careers US or Careers UK.

We’d love to connect.

Open Positions
Sorry, there are currently no open positions available. Please check back soon!
Sorry, there are currently no open positions available. Please check back soon!
Sorry, there are currently no open positions available. Please check back soon!

Contact Us

Eliem Therapeutics, Inc.
PMB #117
2801 Centerville Road, 1st Floor
Wilmington, DE 19808-1609

Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT